Vasco Oliveira

发表

Monitoring a Nuclear Factor-κB Signature of Drug Resistance in Multiple Myeloma*

S. Eschrich, Lili He, J. Cheng, 2011, Molecular & Cellular Proteomics.

Monitoring a Nuclear Factor- (cid:1) B Signature of Drug Resistance in Multiple Myeloma*

S. Eschrich, Lili He, J. Cheng, 2011 .

Bortezomib salvage followed by a Phase I/II study of bortezomib plus high‐dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma

W. Dalton, D. Sullivan, J. Pidala, 2012, British journal of haematology.

A Novel PAAD-containing Protein That Modulates NF-κB Induction by Cytokines Tumor Necrosis Factor-α and Interleukin-1β*

A. Godzik, John Calvin Reed, C. Stehlik, 2002, The Journal of Biological Chemistry.

Experimental Therapeutics , Molecular Targets , and Chemical Biology Targeting the Fanconi Anemia / BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma

W. Dalton, D. Boulware, L. Hazlehurst, 2009 .

The mRNA surveillance protein hSMG-1 functions in genotoxic stress response pathways in mammalian cells.

L. Maquat, J. Brognard, R. Tibbetts, 2004, Molecular cell.

A novel PAAD-containing protein that modulates NF-kappa B induction by cytokines tumor necrosis factor-alpha and interleukin-1beta.

A. Godzik, John Calvin Reed, C. Stehlik, 2002, The Journal of biological chemistry.

Heterotypic interactions among NACHT domains: implications for regulation of innate immune responses.

John Calvin Reed, K. Welsh, J. Damiano, 2004, The Biochemical journal.

Kinome Sirna Screen Identifies SMG-1 as a Negative Regulator of Hypoxia-inducible Factor-1α in Hypoxia*

W. Dalton, Jiing-Dwan Lee, C. Fearns, 2009, The Journal of Biological Chemistry.

A Protective Role for the Human SMG-1 Kinase against Tumor Necrosis Factor-α-induced Apoptosis*

W. Dalton, R. Abraham, F. Mercurio, 2008, Journal of Biological Chemistry.

Characterization of the human GARP (Golgi associated retrograde protein) complex.

R. Schwarzenbacher, I. Meinhold-Heerlein, M. Jung, 2005, Experimental cell research.

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

N. Lee, J. Pinilla-Ibarz, A. Kozikowski, 2019, Scientific Reports.

Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

N. Lee, J. Pinilla-Ibarz, A. Kozikowski, 2019, Scientific Reports.